Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.
Eur J Neurol. 2010 May;17(5):740-5. doi: 10.1111/j.1468-1331.2009.02925.x. Epub 2010 Jan 7.
KIF1B gene represents the first non-inflammatory gene with a putative role on axonal loss and neurodegeneration found to be associated with multiple sclerosis (MS). The objective of this study is to test the association of the rs10492972 C allelic variant of KIF1B gene in a large Italian cohort of patients with primary progressive and progressive relapsing MS (PPMS and PRMS), which represents a subtype of MS mainly driven by neurodegenerative phenomena.
rs10492972 has been genotyped in an outbred sample of 222 primary PPMS and PRMS and 221 healthy controls of unique northern Italian origin using the TaqMan assay.
A non-significant age- and sex-adjusted odds ratio of 0.96 [95% confidence interval (CI) 0.71-1.31] has been found in C carriers, and a non-significant risk of 0.99 [95% CI 0.77-1.63] in C carriers according to a dominant model. Stratification by sex, age at onset younger than 35 years and symptoms at the onset of the disease did not reveal any significant findings. No influence on disability progression, measured with the multiple sclerosis severity score, was found in C carriers.
These results suggest that there is no effect in carrying the rs10492972 C variant on the risk of disease as well as on the rate of disability progression in a cohort of Italian patients with PPMS and patients with PRMS. These data need to be confirmed in an independent sample of patients with progressive MS.
KIF1B 基因是第一个与多发性硬化症(MS)相关的具有潜在轴突丢失和神经退行性作用的非炎症基因。本研究旨在检测 KIF1B 基因 rs10492972C 等位变异在意大利大型原发性进展型和进展复发型 MS(PPMS 和 PRMS)患者队列中的相关性,该队列代表主要由神经退行性现象驱动的 MS 亚型。
使用 TaqMan 法对来自独特的意大利北部起源的 222 例原发性 PPMS 和 PRMS 患者和 221 例健康对照者的外群体样本进行了 rs10492972 的基因分型。
在调整年龄和性别后,C 携带者的非显著年龄和性别调整比值比为 0.96(95%置信区间[CI]0.71-1.31),根据显性模型,C 携带者的风险非显著为 0.99(95%CI0.77-1.63)。按性别、发病年龄小于 35 岁和疾病发病时的症状分层,未发现任何显著发现。C 携带者的残疾进展,用多发性硬化严重程度评分测量,没有发现任何影响。
这些结果表明,在意大利 PPMS 患者和 PRMS 患者队列中,携带 rs10492972C 变异体对疾病风险以及残疾进展率没有影响。这些数据需要在独立的进展性 MS 患者样本中得到证实。